What is Quantum SI?
Founded in 2013, Quantum-Si is a biotechnology firm specializing in the development and manufacturing of advanced testing equipment for protein sequencing. Their proprietary platform enables researchers to analyze proteins at the molecular level, aiming to broaden access to these critical capabilities for laboratories globally. This technology is pivotal for accelerating biological discoveries and advancing human health research. Operating within the life sciences and medical technology sectors, Quantum-Si is publicly traded on Nasdaq, highlighting its established presence and growth within the industry.
How much funding has Quantum SI raised?
Quantum SI has raised a total of $100.3M across 2 funding rounds:
Debt
$350K
Stock/Share Issuance
$100M
Debt (2020): $350K with participation from PPP
Stock/Share Issuance (2025): $100M, investors not publicly disclosed
What's next for Quantum SI?
With the recent major strategic investment, Quantum-Si is poised for accelerated growth and further innovation in protein sequencing technology. This significant capital injection is expected to fuel the expansion of its research and development initiatives, enhance manufacturing capabilities, and broaden its market reach. The company's focus on democratizing protein analysis suggests a strategic push towards making its advanced tools more accessible to a wider range of scientific institutions, potentially leading to breakthroughs in diagnostics and therapeutic research. The enterprise-level funding context points towards Quantum-Si entering a phase of significant scaling and market penetration.
See full Quantum SI company page
